Scopio Labs Closes $50M Investment to Analyze Blood Samples With New Tech

Scopio Labs has announced that it closed a $50M Series C investment round to further advance its end-to-end hardware and software platform that digitizes, quantifies, and analyzes hematology samples. The company is the first of its kind to offer a full-field digital cell morphology solution. 

The Series C round includes names like OurCrowd, Aurum Ventures, Mizrahi-Tefahot Bank Invest, and Ilex Medical. There was participation from other strategic investors in the field and existing investors as well.

X100 Device

Scopio has developed a full end-to-end workflow to digitize and analyze blood samples. It’s major technology is the custom “X100” digital slide-scanning device. The X100 relies on computational photography to produce ultra-high-resolution images of entire sample slides. 

The X100 enables the full digitized slide to be scrolled and zoomed at 100x magnification, which results in ultra-sharp views of individual cells. The Scopio images can then be scanned and accessed anywhere, meaning hematopathologists and clinicians in the lab are not required to stay and review the microscope. 

Itai Hayut is Scopio co-founder and CEO.

“Deep Learning can analyze hundreds of times more healthcare data from a patient, supporting physician decisions and detecting conditions like cancers, anemias, and bleeding disorders, as well as infections and allergies. But for us it all begins with high-quality digital imaging data,” said Hayut. 

AI-Based Solutions

Scopio’s technology provides high-quality images of slides for the first time ever. To analyze these slides, the company has also developed AI-based decision-support solutions. It is also working on other AI solutions, such as one for bone marrow aspirates (BMA). Experts can use the FDA-approved Full-Fueled Peripheral Blood Smear (Full-Field PBS) Application for the detection, pre-classification, and quantification of blood cells. 

The new developments from Scopio come as remote-work continues to increase, and the company is helping aid this advancement in the fields of hematology and cell morphology by building the new subfield of telehematology. 

“In the 21st century, people shouldn’t be looking through microscopes, manually counting cells,” said Hayut. “Scopio’s full-field imaging and AI platform means tens of thousands of cells in a single sample can be examined, counted and analyzed instantly and reviewed by a specialist regardless of location, leading to faster, easier and earlier detection and diagnosis of cancers and many other life-threatening medical conditions.”

Morris Kahn is founder of Aurum Ventures. 

“Scopio was able to develop the platform to move a whole medical discipline onto a digital solution. This is fascinating on the technology side and, most importantly, it will be a game changer for early detection which will save lives. I am excited to see their technology in hospitals and labs worldwide,” he said. 

Scopio is currently being used in top medical centers and labs across the globe. The company employs 85 individuals spread throughout the US, UK, and Israel. It plans to double its number of employees with the new funding, as well as enable new strategic partnerships.